Diligence memo · auto-generated · as of July 2, 2026
Glycomimetics Inc
Glycomimetics Inc looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Glycomimetics Inc operates in Pharmaceuticals, based in Gaithersburg.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Glycomimetics Inc has raised $54M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $39M on 2009-10-20.
Most recent recorded round closed around 2009-10-20.
Valuation (modeled)modeled
Provath models Glycomimetics Inc at approximately $1.3B (range $82M–$5.1B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.56× the median modeled value of Series B Pharmaceuticals companies in 2007–2009 (9 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 8 months.
Last raise 16.7 yr ago; this sector typically re-raises about every 13 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 1.0× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 83% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 91% of those peers.
Closest niche peers: Avid Radiopharmaceuticals, Inc., Virdante Pharmaceuticals, Inc., Sirion Holdings, Inc., Viamet Pharmaceuticals Inc, Aegerion Pharmaceuticals, Inc..
Peoplefiled
8 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.